Institute Of Hematology & Blood Diseases Hospital, China

This study tested whether a combination of venetoclax and azacytidine (or a DA regimen) could prevent relapse in adults with acute myeloid leukemia (AML) who still had measurable disease (MRD positive) after standard chemotherapy. The goal was to extend the time patients stayed i…

This early-phase study tested a drug called Linperlisib in adults with autoimmune hemolytic anemia (AIHA) whose disease did not get better after at least two prior treatments. The goal was to see if the drug could improve red blood cell counts and reduce symptoms. Only 4 people t…

This study tested a low-dose chemotherapy drug called decitabine in people with a severe type of anemia that did not get better with standard treatments. The goal was to see if the drug could improve blood cell counts. However, the study was stopped early after enrolling only 3 p…

This early-phase study tested a new cell therapy (LCAR-AMDR cells) in 4 people with acute myeloid leukemia that had come back or not responded to standard treatments. The therapy uses specially engineered immune cells to target two proteins on leukemia cells. The study was termin…

This study aimed to find how often IDH1/2 gene mutations occur in adults with acute myeloid leukemia (AML) in China and how these mutations affect patient outcomes. Researchers analyzed stored leukemia samples from over 1,000 patients. The study was terminated early, but the data…